“…A number of FLI and/or PAI probes targeted to bacteria have been developed by using antibiotics (vancomycin 19,20 or teicoplanin 21 , specific to Gram-positive bacteria), Concanavalin (targeting bacterial cell-surface mannose) 22 , antibodies (targeting the immunodominant staphylococcal antigen A, specific to S. aureus) 23 , boronic-acid (targeting bacterial cell-surface glycoproteins, specific to Gram-positive bacteria) 24 , enzyme-activated nanoparticles (targeting gelatinase-expressing Gram-positive bacteria) 20 or through electrostatic and hydrophobic interactions (specific to Gram-positive bacteria) 25 . Preclinical evaluation of these probes showed promising results in FLI 19,[22][23][24] or PAI 20,21 of some bacterial infections. Unfortunately, targeting the bacterial cell wall potentially limits the amount of signaling agent taken up leading to lower sensitivity.…”